由于索马鲁肽专利到期，印度计划到 2026 年鼓励国内生产 GLP-1 药物。 India plans to incentivize domestic production of GLP-1 medications by 2026 due to semaglutide patent expiration.
由于 GLP-1 激动剂索马鲁肽的专利即将到期，印度计划到 2026 年鼓励国内生产治疗肥胖症和糖尿病的 GLP-1 药物。 India plans to incentivize domestic production of GLP-1 medications, which treat obesity and diabetes, by 2026, as patent on semaglutide, a GLP-1 agonist, is set to expire. 开发 GLP-1 药物的印度公司已申请政府的生产挂钩激励 (PLI) 计划，并将在 2026 年开始生产后获得激励。 Indian companies developing GLP-1 drugs have applied for the government's Production-Linked Incentive (PLI) scheme and will receive incentives once they begin manufacturing in 2026. 到 2030 年，减肥药物市场规模预计将达到 1000 亿美元。 By 2030, the market for anti-obesity medications is expected to be worth $100 billion.